Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immusoft logo — Cell therapy company dedicated to improving the lives of pat...

Immusoft

Cell therapy company dedicated to improving the lives of patients with rare diseases

Founded 2009 United States Seattle, United States 22 employees Grant Total: $49.27M Biotechnology, Health Care +2

General Information

Company Name Immusoft
Founded Year 2009
Location United States Seattle, United States +2
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Grant
Social

Get notified when Immusoft moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immusoft

Immusoft, a pioneering cell therapy company, is committed to revolutionizing treatments for patients suffering from rare diseases. Utilizing a cutting-edge technology platform known as Immune System Programming (ISP™), Immusoft modifies a patient's B cells to act as miniature drug factories, producing gene-encoded medicines designed to provide long-term therapeutic benefits. This technique offers a novel approach to sustained protein delivery, promising years of relief for patients.

Established in 2009 and headquartered in Seattle, WA, Immusoft operates within the Biotechnology, Health Care, Health and Wellness, and Life Sciences sectors. As of its last financial update, the company secured an $8.00M Grant investment from the California Institute for Regenerative Medicine on 27 January 2023. This infusion of capital underlines confidence in Immusoft's innovative mission to tackle rare diseases.

Taxonomy: Cell Therapy, Rare Diseases, Therapeutic Proteins, Immune System Programming, B Cell Modification, Gene-Encoded Medicines, Miniature Drug Factories, Sustained Drug Delivery, Gene Editing, Biologics Production, Caltech Licensing, Immune System Reprogramming

Services & Products

B Cell Programming
Therapeutic Protein Development
Clinical Research and Development
Biologics Optimization

Target Customers

Patients with Rare Diseases Biopharmaceutical Companies Healthcare Providers Research and Development Organizations

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 27 Jan 2023
Grant •••••• 1 •••• •••• 29 Nov 2021
Venture Round •••••• 3
Investor Investor Investor
25 Sep 2020
Grant •••••• 1 •••• •••• 25 Sep 2020
Series B •••••• 7
Investor Investor Investor Investor Investor Investor Investor
03 Jan 2019

View All 12 Funding Rounds

Immusoft Alternatives & Competitors

View All Alternatives
Immusoft vs
Edity Therapeutics
Edity Therapeutics Israel

Using human immune cells to deliver therapeutic proteins

Seed
22 employees
Biotechnology, Health and Wellness
Immusoft vs
Harpoon Therapeutics
Harpoon Therapeutics United States

SPEARHEADING IMMUNOTHERAPIES

Post Ipo Equity
33 employees
Biotechnology, Health Care
Immusoft vs
Umoja Biopharma
Umoja Biopharma

Pioneering advanced immunotherapies to empower the body's innate ability to fight cancer by reengine...

Series C
9 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Immusoft

Cell therapy company dedicated to improving the lives of patients with rare diseases
Immusoft was founded in 2009.
Immusoft is headquartered in Seattle, United States.
Immusoft operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences.
Immusoft has approximately 22 employees.
Immusoft has completed 12 funding rounds, raising a total of $49.27M. The latest funding stage is Grant.
Immusoft offers: B Cell Programming, Therapeutic Protein Development, Clinical Research and Development, Biologics Optimization.
Top alternatives and competitors to Immusoft include Edity Therapeutics , Harpoon Therapeutics, Umoja Biopharma, Janux Therapeutics, Nectin Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immusoft and Edity Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immusoft and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy